Clinical Edge Journal Scan

Factors associated with persistent fatigue in early RA


 

Key clinical point: Patients with early rheumatoid arthritis (RA) presenting with mono- or oligo-arthritis and high perceived disease impact as assessed by Patient Global Assessment (PGA) scores have severe persistent fatigue over time and may benefit from early nonpharmacologic interventions for fatigue.

Major finding: During the 5-year follow-up, the average fatigue score was significantly higher in patients presenting with mono-arthritis (mean difference in fatigue score [β] +4.3 mm; P = .038) and oligo-arthritis (β +4.8 mm; P = .001) vs poly-arthritis at diagnosis, whereas it was significantly lower in patients presenting with poly-arthritis and low PGA scores vs mono- or oligo-arthritis and high PGA scores (β −20 mm; P < .001).

Study details: This study evaluated 1560 and 415 patients with early RA from the Leiden Early Arthritis Cohort and the Treatment in the Rotterdam Early Arthritis Cohort, respectively.

Disclosures: This study was supported by the European Research Council and the Dutch Arthritis Society. The authors declared no conflicts of interest.

Source: Boeren AMP et al. Rheumatoid arthritis presenting with mono- or oligo-arthritis and high VAS remains most fatigued during 5-years follow-up. Rheumatology (Oxford). 2023 (Aug 26). doi: 10.1093/rheumatology/kead429

Recommended Reading

Slight weight gain, no blood pressure increase with low-dose steroids for RA
MDedge Rheumatology
Medicare announces 10 drugs targeted for price cuts in 2026
MDedge Rheumatology
ACR releases guideline for managing ILD in patients with rheumatic disease
MDedge Rheumatology
Commentary: Cardiovascular risk, anti-drug antibodies, and prednisolone in RA, September 2023
MDedge Rheumatology
Precision blood test for rheumatoid arthritis receives Medicare coverage
MDedge Rheumatology
Early glucocorticoid bridging in RA supported by meta-analysis, but concerns remain
MDedge Rheumatology
Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RA
MDedge Rheumatology
Tapering TNFi raises disease flare likelihood in patients with RA even in those in remission
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology
No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA
MDedge Rheumatology